Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AUPH Stock Forecast 2025-2026
$8.80
Current Price
$1.19B
Market Cap
Buy 5
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to AUPH Price Targets
+36.4%
To High Target of $12.00
+13.6%
To Median Target of $10.00
-9.1%
To Low Target of $8.00
AUPH Price Momentum
+17.8%
1 Week Change
+7.6%
1 Month Change
+56.9%
1 Year Change
+0.3%
Year-to-Date Change
-17.5%
From 52W High of $10.67
+69.4%
From 52W Low of $5.20
📊 TOP ANALYST CALLS
Did AUPH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Aurinia is one of their latest high-conviction picks.
Latest AUPH Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, AUPH has a bullish consensus with a median price target of $10.00 (ranging from $8.00 to $12.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $8.80, the median forecast implies a 13.6% upside. This outlook is supported by 5 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joseph Schwartz at SVB Leerink, projecting a 36.4% upside. Conversely, the most conservative target is provided by Douglas Miehm at RBC Capital, suggesting a 9.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AUPH Analyst Ratings
5
Buy
1
Hold
0
Sell
AUPH Price Target Range
Low
$8.00
Average
$10.00
High
$12.00
Current: $8.80
Latest AUPH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AUPH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 16, 2024 | Cantor Fitzgerald | Olivia Brayer | Overweight | Reiterates | $10.00 |
| Sep 9, 2024 | Cantor Fitzgerald | Olivia Brayer | Overweight | Reiterates | $10.00 |
| Sep 6, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $13.00 |
| Mar 1, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $13.00 |
| Feb 23, 2024 | Cantor Fitzgerald | Olivia Brayer | Overweight | Maintains | $10.00 |
| Feb 22, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $13.00 |
| Feb 16, 2024 | RBC Capital | Douglas Miehm | Outperform | Maintains | $8.00 |
| Sep 22, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $15.00 |
| Aug 7, 2023 | HC Wainwright& Co. | Buy | Maintains | $0.00 | |
| Aug 7, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $15.00 |
| Jul 6, 2023 | Cantor Fitzgerald | Olivia Brayer | Overweight | Reiterates | $15.00 |
| May 3, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $14.00 |
| Feb 23, 2023 | RBC Capital | Douglas Miehm | Outperform | Reiterates | $11.00 |
| Jan 4, 2023 | RBC Capital | Douglas Miehm | Outperform | Maintains | $11.00 |
| Nov 7, 2022 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $14.00 |
| Nov 4, 2022 | SVB Leerink | Joseph Schwartz | Outperform | Maintains | $12.00 |
| Nov 4, 2022 | Oppenheimer | Justin Kim | Perform | Downgrade | $0.00 |
| Nov 4, 2022 | RBC Capital | Douglas Miehm | Outperform | Maintains | $10.00 |
| Aug 9, 2022 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $26.00 |
| Aug 8, 2022 | Oppenheimer | Justin Kim | Outperform | Maintains | $13.00 |
Aurinia Pharmaceuticals Inc. (AUPH) Competitors
The following stocks are similar to Aurinia based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Aurinia Pharmaceuticals Inc. (AUPH) Financial Data
Aurinia Pharmaceuticals Inc. has a market capitalization of $1.19B with a P/E ratio of 32.6x. The company generates $247.30M in trailing twelve-month revenue with a 16.1% profit margin.
Revenue growth is +24.2% quarter-over-quarter, while maintaining an operating margin of +37.4% and return on equity of +11.2%.
Valuation Metrics
Market Cap
$1.19B
Enterprise Value
$909.66M
P/E Ratio
32.6x
PEG Ratio
16.3x
Price/Sales
4.8x
Growth & Margins
Revenue Growth (YoY)
+24.2%
Gross Margin
+86.3%
Operating Margin
+37.4%
Net Margin
+16.1%
EPS Growth
+24.2%
Financial Health
Cash/Price Ratio
+26.3%
Current Ratio
5.9x
Debt/Equity
22.2x
ROE
+11.2%
ROA
+5.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Aurinia Pharmaceuticals Inc. (AUPH) Business Model
About Aurinia Pharmaceuticals Inc.
What They Do
Develops therapies for autoimmune diseases.
Business Model
Aurinia Pharmaceuticals generates revenue through the development and commercialization of innovative therapies targeting autoimmune diseases, particularly focusing on nephrology. The company aims to meet unmet medical needs with its flagship product for lupus nephritis, leveraging advancements in biotechnology.
Additional Information
Aurinia is positioned as a significant player in the biotechnology sector, emphasizing personalized medicine and targeted therapy. Its ongoing research and development efforts are crucial for advancing treatment options and improving patient outcomes in autoimmune disease management.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
300
CEO
Mr. Peter S. Greenleaf M.B.A.
Country
Canada
IPO Year
2014
Website
www.auriniapharma.comAurinia Pharmaceuticals Inc. (AUPH) Latest News & Analysis
Latest News
Quick Summary
Aurinia Pharmaceuticals reported Q1 net revenues of $60M, up 25% YoY. Management reaffirmed FY2025 guidance, projecting profit growth to $0.59/share, indicating a positive investment outlook.
Why It Matters
Aurinia's strong Q1 results, significant revenue growth, reaffirmed guidance, and projected profit growth indicate solid financial health, boosting investor confidence and potential for returns.
Source: Seeking Alpha
Market Sentiment:
Positive
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
14 days ago
Quick Summary
Aurinia Pharmaceuticals plans to host a conference call on June 30, 2025, to discuss the results of its Phase 1 study for AUR200.
Why It Matters
Aurinia Pharmaceuticals' conference call on AUR200 Phase 1 study results signals potential advancements in drug development, impacting future stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Aurinia announced positive results from a Phase 1 study of Aritinercept (AUR200), indicating potential progress in its clinical development.
Why It Matters
Positive Phase 1 results for Aritinercept (AUR200) suggest potential for future drug approval, impacting Aurinia's stock value and market position in the biotech sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Aurinia Pharmaceuticals shares rose 6.8% to $8.57 as investors anticipate clinical data for AUR200. Jefferies upgraded its outlook, citing potential insights from the SAD study.
Why It Matters
Aurinia's share price surge reflects investor optimism about promising clinical data for AUR200, which may influence its market potential and strategic positioning.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
Aurinia (AUPH) experienced significant trading volume recently, but current earnings estimate revisions may hinder its upward momentum in the near term.
Why It Matters
Aurinia's significant trading volume indicates heightened interest, but negative earnings estimate revisions suggest potential short-term price pressure, impacting investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Investors should monitor Aurinia Pharmaceuticals (AUPH) stock due to recent significant activity in the options market.
Why It Matters
Increased options activity often signals anticipated volatility or shifts in sentiment, potentially impacting AUPH's stock price and investment strategies.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Frequently Asked Questions About AUPH Stock
What is Aurinia Pharmaceuticals Inc.'s (AUPH) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Aurinia Pharmaceuticals Inc. (AUPH) has a median price target of $10.00. The highest price target is $12.00 and the lowest is $8.00.
Is AUPH stock a good investment in 2026?
According to current analyst ratings, AUPH has 5 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.80. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AUPH stock?
Wall Street analysts predict AUPH stock could reach $10.00 in the next 12 months. This represents a 13.6% increase from the current price of $8.80. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Aurinia Pharmaceuticals Inc.'s business model?
Aurinia Pharmaceuticals generates revenue through the development and commercialization of innovative therapies targeting autoimmune diseases, particularly focusing on nephrology. The company aims to meet unmet medical needs with its flagship product for lupus nephritis, leveraging advancements in biotechnology.
What is the highest forecasted price for AUPH Aurinia Pharmaceuticals Inc.?
The highest price target for AUPH is $12.00 from Joseph Schwartz at SVB Leerink, which represents a 36.4% increase from the current price of $8.80.
What is the lowest forecasted price for AUPH Aurinia Pharmaceuticals Inc.?
The lowest price target for AUPH is $8.00 from Douglas Miehm at RBC Capital, which represents a -9.1% decrease from the current price of $8.80.
What is the overall AUPH consensus from analysts for Aurinia Pharmaceuticals Inc.?
The overall analyst consensus for AUPH is bullish. Out of 7 Wall Street analysts, 5 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are AUPH stock price projections?
Stock price projections, including those for Aurinia Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2025 2:13 AM UTC